A Meta-Analysis Assessing the Role of Phosphorylated Tau and Amyloid-Beta on Cognitive Decline in a Preclinical Model Of Alzheimer's Disease by Huber, Colin Michael
A META-ANALYSIS ASSESSING THE ROLE OF 
PHOSPHORYLATED TAU AND AMYLOID-BETA ON COGNITIVE 

























In Partial Fulfillment 
of the Requirements for the Degree 
B.S. in Biomedical Engineering with the Research Option  










COPYRIGHT © 2017 BY COLIN HUBER 
 
 
A META-ANALYSIS ASSESSING THE ROLE OF TAU AND 
AMYLOID-BETA ON COGNITIVE DECLINE IN A PRECLINICAL 





















Dr. Cassie Mitchell, Advisor 
School of Biomedical Engineering 
Georgia Institute of Technology 
 
Dr. Esfandiar Behravesh 
School of Biomedical Engineering 











 I would like to thank Dr. Cassie Mitchell for serving as a persistent mentor and 
role model. I would not have been able to reach my goals without your backing and drive. 
I would also like to thank Grant Coan for his mentorship and for being a constant source 
of feedback and improvement.  Connor Yee has consistently served as a hardworking 
teammate, and he has contributed greatly to our research and this thesis. I would also like 
to thank all the teammates I have worked with over the past two years: Taylor May, who 
taught me the basics and gave me a start in the lab, Apoorva Dhanala, Morgan Brown, 

















TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS iii 
LIST OF FIGURES vi 
LIST OF SYMBOLS AND ABBREVIATIONS vii 
SUMMARY viii 
CHAPTER 
1 INTRODUCTION 1 
2 METHODOLOGY 5 
Systematic Review Process 5 
Inclusion Criteria 5 
3xTg-AD Mouse Model 6 
Morris Water Maze 6 
Novel Object Recognition 7 
Data Normalization 8 
Statistical Analysis 8 
3 RESULTS 10 
Amyloid-Beta Effects on Cognitive Decline 10 
Changes in Total Tau Levels Has No Impact on Cognitive Decline 13 
Phosphorylated Tau Impacts Cognitive Decline 15 
Principal Component Analysis 17 
4 DISCUSSION 19 
           Pathology Changes in Wild Type and 3xTg-AD Mice Lead to Corresponding      
           Cognitive Outcomes 19        
 v 
      Assessing Amyloid-Beta as a Direct Cause of Cognitive Decline 20  
                  Tau and Phosphorylated Tau Pathology   20 
                  Comparing Phosphorylated Tau and Amyloid- Beta 21 
                  Principal Component Analysis Emphasizes Complexity of Alzheimer’s  22 
                  Disease 
5 CONCLUSION AND FUTURE WORKS 24 
       Conclusion  24 




LIST OF FIGURES 
Page 
Figure 1: Pathology Flowchart 4 
Figure 2: Biocuration Process 9 
Figure 3:  Amyloid-Beta Correlation with Cognitive Decline  11 
Figure 4: Individual Amyloid-Beta Form Analysis 12 
Figure 5: Tau Impact on Cognitive Decline 14 
Figure 6: Overall Phosphorylated Tau Impact on Cognitive Ability 16 
Figure 7: Phosphorylated Tau Epitope Analysis 17 
Figure 8: Principal Component Analysis 18 
Figure 9: Summative Figure: Phosphorylated Tau More Directly Impacts Cognitive 








LIST OF SYMBOLS AND ABBREVIATIONS 
 
Aβ, amyloid-β Amyloid-Beta 
AD  Alzheimer’s Disease 
NFT  Neurofibrillary Tangles 
GSK3  Glycogen Synthase Kinase-3 
MWM  Morris Water Maze 
NOR  Novel Object Recognition 
RI  Recognition Index 
3xTg-AD  Triple Transgenic Alzheimer’s Disease Mouse Model 
WT  Wild type mouse model 







Alzheimer’s disease pathology is characterized by the accumulation of 
extracellular amyloid-beta (Aβ) plaques in the brain at onset followed by growth of 
phosphorylated tau proteins into neurofibrillary tangles (NFTs).  Both Aβ plaques and 
NFTs interfere with normal neuronal cell function by disrupting proper synapse function 
at neural junctions and inflicting damage to neurons, eliciting cognitive decline.  Based 
on previous literature, quantified accumulation of Aβ does not correlate with cognitive 
decline.  There have been no FDA-approved drugs capable of curing AD or even 
delaying actual disease progression in patients with research efforts heavily focused on 
Aβ as the primary causative agent in AD pathology.  Phosphorylated tau (pTau) 
accumulation into NFTs more strongly correlates with cognitive decline despite a smaller 
total concentration, and therefore, pTau may contribute more to Alzheimer’s progression.  
We performed a meta-analysis combining and analyzing research studies matching 
inclusion criteria extracted from a database of more than 3,000 Alzheimer’s mouse model 
peer-reviewed articles.  Inclusion criteria encompasses: use of triple transgenic 
Alzheimer’s Disease (3xTg-AD) mouse model, quantification of cognitive performance 
by Morris water maze (MWM) escape latency or Novel Object Recognition (NOR), and 
quantification of Aβ, total tau, and/or pTau levels.  Phosphorylated tau, total tau, and Aβ 
levels were compared to measure the largest impact on cognitive performance by 
correlative assessment with MWM escape latency and NOR.  Results indicate that 
increases in both pTau and Aβ levels in 3xTg-AD mice have significant correlation with 
and prediction of cognitive decline.  Although pTau has a smaller concentration in the 
brain than Aβ, analysis of aggregated data illustrates that pTau has a stronger correlation 
 ix 
with cognitive decline.  The two proteins interact through GSK3β and other 
phosphorylating pathways to cause more rapid cognitive decline, and the onset of Aβ 
may lead to the development of neurofibrillary tangles. Aβ and tau pathologies are 
interwoven in a complex manner that prevents clear separation. Alzheimer’s disease 
treatment will require the removal and subsequent prevention of both proteins' 
accumulation.  The present study concludes that future research should focus on 
combination drugs and defining the connection between Aβ and pTau rather than simply 






Alzheimer’s disease is the leading neurodegenerative disease in the world.  
Currently, 46 million people across the globe are afflicted with dementia (Alzheimer’s 
accounts for around 70% of these cases), and the number is expected to grow to over 130 
million by 2050 [1].  Over the course of 5-10 years, the disease slowly causes brain 
degeneration leading to dementia and eventually the inability to care for oneself.  An 
estimated $818 billion is spent on dementia patient care each year including informal care 
provided and paid directly by family members [1].  The disease is costly to the patients 
financially, but moreover, it is emotionally taxing to their families who must look after 
and watch their loved ones suffer from debilitating cognitive deficits, including loss of 
functional memory, spatial coordination, and even self-identity.  There is no definitive 
cure, and the only treatment simply delays the onset of symptoms without slowing 
disease progression [2, 3]. 
The hallmarks of Alzheimer’s Disease (AD) pathology are marked by accumulation 
of extracellular amyloid-β (Aβ) plaques in the brain followed by intracellular 
neurofibrillary tangle (NFT) growth [4, 5].  Aβ upregulates the generation of NFTs by 
increasing glycogen synthase kinase-3 (GSK-3) activity, leading to the phosphorylation of 
tau (pTau) [6, 7].  Phosphorylated tau begins to self-assemble to form NFTs.  Both Aβ 
plaques and NFTs interfere with normal neuronal cell function by disrupting synaptic 
signaling at neural junctions.  Each protein’s accumulation leads to neuron damage, 
eliciting diminished brain mass and cognitive function (Figure 1) [8].  Phosphorylated tau 
is linked to retarding Aβ growth establishing a negative feedback loop where increases in 
 2 
pTau slows rate of Aβ accumulation [6].  As the disease progresses in late stages, pTau 
continues to form NFTs while Aβ plaque build-up plateaus.  Connections between Aβ and 
pTau are not fully characterized, but current research is striving to completely describe the 
pathology of Alzheimer’s disease.   
The removal of Aβ plaques does not influence elimination of neurofibrillary tangles 
after NFTs have been established in the brain, but early intervention can prevent pTau 
development [9, 10].  Therefore, targeted late stage treatments may specifically eliminate 
Aβ without impacting pTau levels that have already accumulated.  Comparison of 
differences in pTau and Aβ levels in treated mice illuminate differences between the 
proteins’ impact on cognitive function.  For example, phosphorylated tau levels were 
reduced by chemical treatment as Aβ levels continued to increase, yet cognitive function 
improved [11].  With decreasing pTau levels and increasing Aβ levels, cognitive 
improvement emphasizes that there is a quantitative difference between how the two 
proteins effect on cognitive deterioration.  In the present study, relative level changes in 
both proteins were analyzed and correlated with the overall changes in cognitive ability to 
compare the impact.  We also consider the interaction between tau and amyloid-β to 
understand why and how pTau levels decreased and Aβ increased. 
Since the inception of the Amyloid Cascade Hypothesis, amyloid-β has been 
considered the main cause of degeneration in Alzheimer’s, but there have been no 
definitive treatments or cures found to date [12].  The only FDA approved treatments are 
cholinesterase inhibitors, which increase acetylcholine levels to simply suppress the 
cognitive symptoms of Alzheimer’s Disease, and memantine, which regulates glutamate 
to elicit neuroprotective effects but only mild cognitive improvement [2].  These drug 
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treatments simply mitigate the cognitive symptoms of AD without slowing disease 
progression [2, 3].  Treatments targeting Aβ and Aβ precursors have failed to pass clinical 
trials to improve patient outcomes [2, 3].  The presence of Aβ is associated with a decrease 
in cognitive performance; however, the level of Aβ inconsistently predicts the amount of 
cognitive decline [13].  Instead, it is suggested that other Alzheimer’s pathologies, such as 
the hyperphosphorylation of tau, are the functional cause of degeneration after the initial 
onset of disease [8].   
The present study compares the effects of Aβ and phosphorylated tau levels on 
cognitive performance through a large-scale meta-analysis of 3xTg-AD mouse model 
experiments.  The triple-transgenic mouse model (3xTg-AD) of Alzheimer’s expresses 
tangle and plaque pathology as well as synaptic dysfunction  [14].  Aβ deposits first appear 
by 6 months of age while the first detection of phosphorylated tau occurs around 12 months 
of age [14, 15].  The 3xTg-AD mouse model pathology resembles human patients and has 
similar total tau levels in the cerebrospinal fluid [15-17].  The Morris water maze (MWM) 
reliably reflects how degradation of the hippocampus, striatum, basal forebrain, 
cerebellum, and neocortical areas affect cognitive function [18].  Meta-analysis was 
focused on correlations between cognitive performance in the Morris water maze or Novel 
Object Recognition test and amyloid-β and phosphorylated tau levels.  To analyze the 
different Aβ forms and pTau epitopes, specific analyses were conducted (e.g. cognitive 
performance vs. soluble Aβ 42 and AT8 pTau antibody marker). 
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Figure 1. Pathology flowchart explaining connections between amyloid-β and tau 





Systematic Review Process 
 We perform a systematic review, which quantitatively analyzes studies in a 
consistent manner to provide an over-arching view of a field’s aggregated work.  First, a 
series of database searches identified peer-reviewed publications that are likely to meet 
the study’s criteria (Figure 2). These publications are then examined individually to 
determine whether they meet the inclusion criteria (see below).  All quantifiable 
experimental data from figures and tables are extracted into an organized database in a 
process overseen by stringent quality control teams, resulting in transcription accuracy 
greater than 98.8% [19].  Comparable data are compiled to assess overall trends. 
Inclusion Criteria 
 Key terms searches in PubMed were used to identify papers that were likely to 
meet the inclusion criteria.  Search terms included “Alzheimer’s Disease”, “3xTg-AD”, 
“amyloid-beta”, “tau”, “phosphorylated tau”, “glycogen synthase kinase 3”, and 
numerous combinations, variations, and abbreviations of these terms.  For inclusion, 
peer-reviewed scientific studies must contain quantifiable data for either phosphorylated 
tau or Aβ levels and data for either Morris water maze escape latency or novel object 
recognition. Only papers utilizing the 3xTg-AD treated and control groups and published 
in English were included.  Resultant searches led to the construction of a transcribed 
database of 3000 peer-reviewed articles that were assessed for inclusion.  A total of 52 
peer-reviewed journal articles met the required criteria for final inclusion. 
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3xTg-AD Mouse Model  
 The 3xTg-AD mouse model is a complex model with transgenic β-amyloid 
precursor protein (βAPPSwe), presenilin-1 (PS1M146V), and tauP301L gene 
replacements [15].  As in human Alzheimer’s Disease pathology, both Aβ and pTau 
formation show age- and region-dependence with Aβ plaques forming before the 
accumulation of neurofibrillary tangles [20].  3xTg-AD mice have phosphorylated human 
tau concentrations closer to human levels than P301L and Tg4510 transgenic AD mouse 
models [16]. Amyloid-β, total tau, and phosphorylated tau measurements were used from 
the mouse hippocampus for consistency and to assess the most direct impact on the 
morphological site of learning ability.  Functional cognitive deficits appear as early as 4 
months of age in the 3xTg-AD mice, a timeline that aligns with the formation of 
intracellular deposits of amyloid-beta in the hippocampus [21].  Both Aβ and pTau 
accumulate in significant levels in the brain after 8-12 months to contribute to cognitive 
deficits.  The complex pathology in 3xTg-AD mice enables quantitative comparisons of 
Aβ and NFTs, as well as the ability to investigate possible interactions between Aβ and 
phosphorylated tau pathology. 
Morris Water Maze 
 The Morris water maze (MWM), which tests spatial memory, was used as the 
primary measure of cognitive performance.  The MWM is the de facto industry standard 
for cognitive tests for mouse models and was chosen because of its prevalence in AD 
experimental studies. A mouse is placed into a pool of water and trained to search for a 
visible platform in an open, cold (13°C) bath [22, 23].  After one day of training with the 
platform visible above water, the mouse is again placed in the maze with the platform 
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hidden below the water and uses visual cues outside of the bath to find the platform 
location. Training with the hidden platform continues four times a day for five to seven 
days. The time it takes for the mouse to find the platform is measured as the mouse’s 
escape latency [24].  Escape latency data from day five was analyzed because it most 
highlights differences in learning within the standard practice of five days of training. 
Moreover, overtraining (too many trials per day or too many days of training) can result 
in all mice performing at a disproportionately high level and thus, preventing discernable 
quantitative learning differences [25]. The first two trials on day one serve as a control 
between mice for swimming performance and ability; mouse groups should not 
significantly differ on day one escape latency [23].  
Novel Object Recognition 
Due to the perceived limitations of the Morris water maze (e.g. mice are less 
suited to the task than rats, the stress caused by cold water may affect the results, it only 
tests spatial memory, etc.), novel object recognition (NOR) was used as a second measure 
of cognitive performance [26, 27].   NOR introduces mice to a new object and a familiar 
object to which the mouse had previously been exposed.  Memory is then tested by the 
relative amount of time spent exploring the new object based on remembering the 
familiar object [28].  We chose recognition index (time spent exploring the novel object/ 
total time exploring) as the standard measurement for NOR.  In cases where only percent 
time spent with novel object or discrimination index was provided, recognition index was 
calculated.  Novel object recognition avoids stress on the mice and other factors such as 
swimming capability inherent to the Morris water maze.  However, the disadvantage of 
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the NOR compared to the MWM is the inability to differentiate between the spatial and 
non-spatial conditions of the task [29]. 
Data Normalization 
All data was normalized against untreated control 3xTg-AD mice within the same 
study to achieve a consistent baseline.  Phosphorylated tau and amyloid-β were rarely 
measured in wild type (WT) mice, so WT mice could not be used as the primary control.  
Moreover, phosphorylated tau is usually measured in arbitrary units.  A percent control 
calculation expresses a normalized data value: (Day 5 Escape Latency of treated 3xTg-AD 
experiment group) / (Day 5 Escape Latency of untreated 3xTg-AD control group) X 100%.  
Protein level can substitute for escape latency in the example above to attain equivalent 
percent control values for amyloid-β and pTau.  There were no significant differences in 
variance (F-test p = 0.8453) or mean (t-test p = 0.5008) between MWM data normalized 
to day one compared to the non-normalized counterpart.  Day 1 MWM training on a visible 
platform is consistent for all mice, so escape latency data was not normalized to day 1 to 
minimize data processing and alteration.  When corresponding data was available, the same 
normalization was applied to wild type mice to assess relative protein levels and escape 




We examined the correlation of escape latency or recognition index against tau, 
phosphorylated tau, and Aβ levels by performing a Pearson coefficient correlation 
analysis at alpha level 0.05.  After determining significance, Pearson coefficient and 
slope allow comparison of the strength of the correlation.  The Igor analytical software 
(Wavemetrics, Inc.)  was used to calculate the line of best fit and the corresponding R2 
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values.  A principle component analysis was used to evaluate variance among kinases 
involved in the phosphorylation of tau; results were generated utilizing the built-in PCA 
function in MATLAB (The MathWorks, Inc.).  A multiple linear regression also directly 
compared pTau and Aβ in studies that analyzed both protein levels; the MATLAB 
stepwise function established correlation factors between cognitive performance and 
protein variables at α = 0.05 for significance.  Clear outliers (9 data points) were 
eliminated by the Grubb test; graphical depiction and statistical analysis presented in the 
Results are without outliers. 
 











Amyloid- β Effects on Cognitive Decline 
A comparison between Aβ, total tau, pTau, and cognitive function for 3xTg-AD 
mice contained over 300 mice from over 50 peer-reviewed scientific papers [17, 30-80].  
Correlation of the relationship between total Aβ plaque levels and day five Morris water 
maze escape latency was measured by meta-data analysis (Figure 3A).  Data points 
represent the aggregated average of a group of mice from a single experiment, where the 
line of best fit is weighted based on sample size for each aggregate point. Data point 
weighting and hippocampal protein measurements was consistent across all correlation 
analysis within our study.   The Grubb outlier test identified 9 definitive aggregate data 
points as outliers, which were ultimately removed to ensure integrity of the analysis.  We 
plotted the experimentally treated mouse escape latency normalized to a 3xTg-AD control 
mouse against the normalized total Aβ levels (Figure 3A).  Total Aβ had a significant 
correlation to MWM escape latency (p = 6.2768e-11), but it was a very weak trend (R2 = 
0.148971).  To support results in the Morris water maze, an equivalent test and set up was 
run for Novel Object Recognition (Figure 3B).  NOR recognition index scores agreed with 
the results in MWM with a significant but very weak trend (p = 0.0137, R2 = 0.06369).  
To compare levels of each Aβ form (soluble Aβ42, soluble Aβ40, insoluble Aβ42, 
and insoluble Aβ40), individual analysis on the relationship between cognitive function 
and levels of each Aβ was completed.  Percent control escape latency in the MWM at day 
five was plotted against each individual percent control in Aβ (Figure 4).  Both soluble  
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Figure 3. Increases in amyloid-β plaque level weakly correlates with decline in performance 
in both the Morris water maze and the Novel Object Recognition test. A) A positive trend 
indicates that as Aβ increases, cognitive performance declines (slope = 0.33614, R2 = 0.148971, n 
= 259).  The red target markers provide a visual reference for wild type mouse measurements in 
comparison to 3xTg-AD control mice. B) Novel object recognition correlation results in similar 
significant, weak trends, where a negative trend indicates decreased cognitive function with Aβ 
increases (slope = -0.15599, R2 = 0.06369, n = 116). 
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Aβ forms showed weak, but significant trends with cognitive function (n = 148, p = 
6.4058e-11, slope = 0.14792, R2 = 0.247293; p = 1.2842e-07, slope = 0.13503, R2 = 0.1667, 
for Aβ40 and Aβ42, respectively) (Figure 4A & 4C).  Insoluble Aβ40 and Aβ42 showed 
no significant correlation with MWM escape latency (Figure 4B & 4D).  Both trends had 
nearly flat lines with very low R2 values indicating that insoluble Aβ levels did not correlate 
with cognitive function (R2 < 0.00125, slopes < 0.005, p > 0.44, n = 144).  Amyloid-β data 
measurements fell into two main categories: direct (staining and imaging of plaques or 
western blot with total Aβ marker like 6E10) and indirect (calculated combination of Aβ 
individual forms).  The direct measurements had a significant correlation with escape 




Figure 4. Correlation analysis of each major amyloid-β form to Morris water maze escape 
latency.  A, C) The soluble forms of Aβ showed significant correlation with escape latency 
performance, and the slope of the trend was similar to total Aβ (n = 148; Aβ40: slope = 0.14792, 
R2 = 0.24729; slope = 0.13503, R2 = 0.1667. B, D) Neither Insoluble Aβ40 nor Aβ42 displayed 
significant trends with cognitive function (p = 0.4865, p = 0.4470, respectively). E) Direct Aβ had 
a significant trend with cognitive function (slope = 0.9009, R2=0.4640, n = 93). 
Changes in Total Tau Levels Has No Impact on Cognitive Decline 
After confirming previous results that Aβ and its subforms only weakly correlates 
with cognitive function in the Tg2576 model, total tau and phosphorylated tau were 
analyzed for their contributions to Alzheimer’s pathology [13].  Total Tau 
(unphosphoryated + phosphorylated tau) showed no significant trend in either Morris 
water maze or Novel Object Recognition (Figure 5).  Total tau, also referred to as tau in 
the present study, is measured by anti-human tau antibody HT7 or Tau-5 which bind to 
location on tau that allow recognition of both unphosphorylated and phosphorylated tau 
[81, 82].  In fact, the trend slopes even indicate increases in total tau improve cognitive 
function.  Most data points were centralized around 100% of control for total tau 
indicating total tau levels in treated mice did not change much compared to the control.  
Pearson coefficient analysis for escape latency versus total tau produced a p value of 
4.5447e-04 and R2 = 0.0709 (n = 152).  Novel object recognition had a nearly flat trend 
line with most tau data again clustered around 100% of control (p = 0.2510, R2 = 
0.005517, slope = 0.04653, n = 85). 
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Figure 5.  Total tau does not significantly correlate with cognitive decline measured 
by the Morris Water Maze or Novel Object Recognition. A) There was a weak, 
significant trend for day five escape latency with total tau levels (p = 4.5447e-04, fit = 
90.936 – 0.17679x, R2 = 0.0709, n = 152). B) Tau levels did not correlate significantly 
with performance in the Novel Object Recognition test (p = 0.2510).   
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Phosphorylated Tau Impacts Cognitive Decline 
Although analysis of total tau showed no association with cognitive ability, 
phosphorylated tau has a significant association with cognitive ability through both 
Morris water maze and Novel object recognition correlations (Figure 6).  Phosphorylated 
tau was measured through western blot, imaging of the hippocampus, or ELISA.  In all 
cases, expression units were presented as relative to a 3xTg-AD control.  Imaging of 
immunohistologically marked phosphorylated tau provides direct measurement of 
neurofibrillary tangles.  The other measurements also indicate hyperphosphorylation and 
accumulation of NFTs. 
Phosphorylated tau correlation with Morris water maze escape latency surpassed 
amyloid-β with a steeper slope of 0.40837 and R2 = 0.2753. To confirm the comparison 
between pTau and Aβ, the proteins were used as variables to predict escape latency 
performance in a multiple linear regression.  Using the MATLAB stepwise function on 
data points where pTau and Aβ were available, it was determined that pTau was a stronger 
variable input for predicting cognitive function than Aβ.  Both variables considered alone 
were significant factors for improving correlation, but adding Aβ variable to the pTau 
trendline did not significantly improve correlation (data not shown). 
Phosphorylated tau epitopes are expressed inconsistently between papers as well 
as within the same paper.  There is not a definitive epitope that is considered the most 
impactful or completely irrelevant.  AT8, AT270, AT180, and PHF-1 monoclonal 
antibody markers were compared to determine if one had a more consistent measurement 
and correlation with MWM performance (Figure 7).  Both AT8 and AT270 were 
significant and had relatively strong, positive correlation coefficients (r = 0.7217 and r = 
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0.8280).  PHF-1 and AT180 had no significant trends with escape latency, and they even 
have negative slopes (r = -0.0646 and r = -0.4922).   
 
Figure 6.  Phosphorylated Tau correlates with both cognitive function tests. A) A significant 
positive slope with escape latency indicates cognitive function decreases as pTau levels increase 
(p < 1.0e-15, fit = 41.85+ 0.40837x, R2 = 0.2753, n = 371). B) A significant negative slope with 
Novel Object Recognition indicates cognitive function decreases as pTau levels increase (p = 
0.0117, fit = 14.294 – 0.31962x, R2 = 0.1763, n = 113).  
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Figure 7.  Phosphorylated tau epitope analysis comparing different phosphorylation 
locations.  Phosphorylated Tau epitope breakdown shows strong positive correlations with AT8 
(A) and AT270 (B) while showing no trend or a weak, negative trend with PHF-1(C) and AT180 
(D).  A) AT8: fit = 28.3 + 0.58555x, p < 1.0e-15, R2 = 0.5209, n = 185.  B) AT270: fit = 25.39 + 
0.61933x, p < 1.0e-15, R2 = 0.685582, n = 88.  C) PHF-1: Fit = 72.638 - 0.01739x, p = 0.3295, R2 
= 0.004179, n = 48.  D) fit = 94.28 - 0.2854x, p = 3.4486e-04, R2 = 0.2423, n = 44.  Sample sizes 
noticeably decreased from A to D due to a lack of data and measurements using the AT180 and 
PHF-1 markers.  
 
Principal Component Analysis 
A principal component analysis (PCA) calculated contribution of individual 
components to variance in the data and provided an overall assessment of disease 
complexity.  Additionally, kinases involved in tau phosphorylation (pGSK3β, GSK3β, 
p25, and p35) were analyzed to identify possible targets for future research (Figure 8).  
PCA calculates components that explain the largest amount of variance, whereas a biplot 
displays how much variables contribute to variance for a particular component.  Six 
outlier data points were removed from Figure 8A-C for the analysis in 8D-F; although 
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appearing different at first, the important considerations are orthogonality of the variables 
and overall contribution to variance explained.  Correlating variables cluster together on 
the biplot and contribute similarly to variance of the pathological “system”. 
Phosphorylated GSK3β contributed most strongly to variance in the “system”, and pTau 
and MWM escape latency contribute to variance in a collinear manner.  
 
Figure 8.  Principal component analysis to determine variance contribution of the key 
components in tau phosphorylation. (A-C) PCA on all data with no outlier removal graphed in 
a biplot (A) and broken down to clearly show the first two components (B, C). Component 1 
accounted for 63.6% of the variance, and component 2 accounted for 27.9%.  (D-F) PCA on data 
with six outliers removed displayed in a biplot (A) and broken down to show the first two 
components (E, F). Component 1 accounted for 86.6% of the variance, and component 2 






Total direct Aβ and phosphorylated tau both correlated with cognitive decline in 
the Morris water maze and Novel object recognition.  However, phosphorylated tau had a 
stronger and more definitive trendline, indicating that with a lower overall concentration, 
pTau has a stronger connection to cognitive ability in transgenic mice than does Aβ [83].  
Individual Aβ form analysis supports previous findings that Aβ correlates weakly with 
cognitive decline and has a limited effect on cognitive changes [13].  Inconsistent trends 
amongst the pTau antibodies presents an interesting discussion on the quality of pTau 
epitope markers and phosphorylation location influence on self-assembly into 
neurofibrillary tangles.  Principal component analysis emphasized the need for further 
investigation of tau phosphorylation mechanisms and the intricate complexity of 
Alzheimer’s Disease pathology, which suggests the need for combinatorial therapeutic 
strategies. 
Pathology Changes in Wild Type and 3xTg-AD Mice Lead to Corresponding 
Cognitive Outcomes 
Relative pTau and Aβ protein levels of wild type mice to 3xTg-AD control mice 
coincided with relative escape latencies of treated 3xTg-AD mice with a similar reduction 
in pTau and Aβ.  A 50% decrease in pTau led to a 30-50% reduction in escape latency for 
both treated 3xTg-AD and wild type mice.  The alignment of wild type data supports the 
validity and consistency of using 3xTg-AD control mice.  Moreover, wild type mice 
provide the lower limit on how fast the mice can swim and find the platform with no 
Alzheimer’s Disease pathology [25].  
 20 
Amyloid-β Displays Weak Trends with Cognitive Ability 
Total amyloid-β showed only weak trends with cognitive decline, which was 
supported by the individual analysis of the four main forms of the Aβ components.  
When total amyloid-β was not measured, the four Aβ forms presented in this study were 
added together for a total Aβ calculation.  As expected, the trends with insoluble Aβ were 
insignificant and not an indication of cognitive decline.  Despite insoluble Aβ typically 
having higher concentrations in the brain, relative changes in soluble Aβ levels had a 
larger impact on cognitive function [36, 57, 76].  The diffuse nature of soluble Aβ allows 
it to have a more direct impact on neurons by surrounding the cell surface and synapses 
leading to neurotoxicity [84-86].  The connection between Aβ and tau phosphorylation is 
not well defined, but significant trends could indicate soluble Aβ oligomers have a 
stronger influence in activating kinases for tau phosphorylation [87].  Direct Aβ 
measurements correlated strongly with escape latency (R2 = 0.769 , r = 0.8768) (Figure 
2E), but pTau correlated even more strongly with escape latency for points where pTau 
measurements were available (9 out of 12 data points available; R2 = 0.847, r = 0.9204).  
These trends support the indirect role that amyloid-β plays in the Amyloid Cascade 
Hypothesis, but the variance and weak trendlines reinforce the complexity of the 
interaction.  Thus, while amyloid-β may be the most physically visible marker of AD, it’s 
actual role in the disease etiology, and namely, cognitive decline, is neither independent 
nor direct, but rather, intertwined with mechanisms like pTau and GSK-3. 
Total Tau and Phosphorylated Tau Pathology 
Total tau did not have a clear impact on cognitive decline, and trends even 
indicated that it may improve cognitive ability.  The result is unsurprising considering tau 
is a normal and prevalent protein in the brain that is needed for microtubule stabilization 
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and proper neuron function [88, 89].  Additionally, tau does not aggregate into NFTs 
even when overexpressed because of its natural high solubility [90].  Trends were unclear 
because tau in treated mice did not differ from the control mice substantially in many 
experiments; the measurements tended to be within 10-20% of the control value.  Such a 
sensitive range may not allow meaningful assessment of cognitive impact with MWM 
and/or NOR, especially in a complex disease with numerous other contributing factors. 
Phosphorylated tau, however, showed strong trends with cognitive performance in 
both cognitive tests.  Individual breakdown of pTau epitopes (AT8, AT180, AT270, and 
PHF-1) revealed there were differences in predicting cognitive function.  AT8 and 
AT270 had a strong correlation between increasing levels and cognitive decline; 
however, AT8 had more supporting data that promoted a strong correlation between 
increased pTau levels and increased latency in the Morris water maze.  Therefore, AT8 
could be the most effective and consistent method in measuring phosphorylated tau level.  
Both PHF-1 and AT180 resulted in very low correlation between escape latency and 
pTau levels, but both trends could have been impaired by insufficient sample size.  
Further research on the binding characteristics is needed to understand accuracy of 
measurement and to consistently explain differences in measurements.  The presented 
results of our aggregated analysis beg the question, “Is there a lack of consistency 
between the experimental antibodies, or does phosphorylation location impact the ability 
to self-assemble into neurofibrillary tangles?” 
Comparing Phosphorylated Tau and Amyloid-Beta 
Phosphorylated tau has a significantly more powerful impact on cognitive 
function than amyloid-β, especially considering pTau deposits are not as substantial, in 
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terms of visual prevalence and concentration in cerebrospinal fluid in the brain [83, 91].  
Phosphorylated tau is most likely the primary factor in cognitive decline, though Aβ may 
play an indirect role in Alzheimer’s pathology for development of neurofibrillary tangles.  
Based on the 3xTg-AD mouse model, Aβ is the first developing pathology in 
Alzheimer’s disease, suggesting that it may serve as the first link in the chain leading to 
neurodegeneration by influencing tau phosphorylation.  Our conclusions support findings 
of previous studies; Foley et al. indicates that Aβ may cause some cognitive decline when 
highly concentrated, but shows that quantitative levels do not correlate with cognitive 
decline.  In contrast, levels of pTau do significantly and directly correlate with cognitive 
decline, and therefore, pTau could be a key functional treatment target even in later 
stages of the AD pathology.  The connection between phosphorylated tau and amyloid-β 
requires further research to define.  It is likely, however, that Aβ indirectly promotes tau 
phosphorylation through upregulation of kinases such as GSK-3β and p25, which 
phosphorylate tau.  
Principal Component Analysis Emphasizes Complexity of Alzheimer’s Disease 
Glycogen synthase kinase-3 (GSK-3), p25, p35 are kinases involved in the 
phosphorylation of tau as an important step in AD pathology [7, 92].  Analysis focused 
around GSK-3 due to its dominance as a tau phosphorylation kinase and prevalence in 
literature; specifically, the GSK-3β isoform is linked more closely with tau pathology 
[92].  In both analyses (Figure 8), the Morris water maze escape latency variance is low 
in both components; this finding is somewhat expected because there is a natural limit to 
the variance in escape latency.  In both analyses, phosphorylated GSK3β (pGSK3β) and 
phosphorylated GSK3β normalized to total GSK3β (pGSK3β/GSK3β) contribute 
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substantially to variance, which highlights them as prime future research targets to assess 
mechanisms directly related to escape latency.  Total GSK3β contributed little to variance 
as most of the values remained around 100% of a 3xTg-AD control mouse; therefore, the 
similar results of pGSK3β and pGSK3β/GSK3β is expected.  Phosphorylated tau and 
latency align in the analysis with outliers and closely in component 1 in the no outliers 
analysis.  These findings suggest the presence of collinearity and provide corresponding 








CONCLUSION AND FUTURE WORKS 
Conclusion 
From the lack of drug development and the corresponding support of large-scale 
meta-analysis, Aβ may not be the most crucial therapeutic target to improve Alzheimer’s 
Disease symptoms (Figure 9).  Future research should focus on eliminating 
phosphorylated tau to reverse Alzheimer’s disease symptoms, rather than focusing solely 
on Aβ elimination.  Due to the complex interactions between multiple proteins, a 
multifaceted treatment approach is the best means by which to combat the disease.  
Furthermore, protein regulator treatments could moderate the activity of kinases like 
pGSK3β to prevent hyperphosphorylation of tau, yet allow normal pGSK3β function 
without complete elimination.  The large variance in all aspects of the trend lines and 
moreover, the number of variance-contributing variables in principal component analysis, 
suggests that many other factors are affecting the overall outcome of cognitive ability in 
AD.  A larger research focus on higher level interactions such as Aβ and GSK-3β with 
tau phosphorylation will give a better understanding of the disease etiology and more 
likely lead to a cure.  Targeting both pTau and Aβ could decrease direct neuron 
disruption and may help prevent subsequent protein accumulation.  The results of this 
systematic review and meta-analysis comparing Aβ and tau steer the field in a new 
direction toward phosphorylated tau and combination therapies to more effectively treat 





 The work presented in this thesis, which comprehensively examined the impact of 
phosphorylated tau and Aβ and their effect on cognitive decline in the 3xTg-AD mouse 
model, will be submitted for peer-review for possible research journal article publication 
in May 2017.  While my future in Dr. Mitchell’s lab will end upon my May 2017 
graduation, new projects will expand off the present work to further assess and compare 
overall data trends in Alzheimer’s disease.  Future studies may include a more in depth 
view into the biochemistry of Aβ and tau pathology, or even a confirmation of results in 
another mouse model.  Directions that would best assist the field for new research routes 
would include informatics analysis of other Alzheimer’s Disease factors such as 
inflammation, oxidative stress, or specific connections of Aβ and pTau to further evaluate 
the Amyloid Cascade Hypothesis or to identify other promising hypotheses. 
 
 
Figure 9.  Summative figure emphasizing the contribution of pTau to cognitive 
decline and the demand for further research in understanding tau phosphorylation 
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